Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$16.34M-$16.34MderivedN/M vs Q4 2016 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$17,029,573N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,282,071N/M Free Cash Flowderived-$1,282,072N/M ended Dec 31, 2017 · filed Apr 2, 2018 · 92 d after period end